ASC30 diabetes trial lowers HbA1c against placebo in 12 week Phase 2 study

HONG KONG, Oct 28. Ascletis Pharma said its ASC30 diabetes trial met its main goal, with the daily pill lowering blood sugar more than placebo over 12 weeks in adults with type 2 diabetes. The company reported a placebo adjusted HbA1c reduction of 1.7 percentage points in its lowest and highest dose groups. The U.S. Phase 2 study enrolled 100 people and lasted 13 weeks. The figures come from a company press release, not a peer reviewed paper. ASC30 is an investigational small molecule, not a peptide, that targets the GLP 1 receptor.

What the ASC30 Phase 2 results show

The ASC30 diabetes trial was randomized, double blind and placebo controlled, and it ran at multiple U.S. sites, according to the company's topline results announcement. Adults entered with HbA1c between 7.0% and 10.5%, and the group averaged 8.3% at the start. Participants were assigned in a rough 2:3:3:2 ratio to three maintenance dose levels or matching placebo tablets. The primary endpoint was the change in HbA1c at 12 weeks compared with placebo. Ascletis reported placebo adjusted drops of 1.7, 1.6 and 1.7 percentage points across the low, middle and high dose groups, with a p value below 0.0001. The company said type 2 diabetes is the second indication it is developing for ASC30, after obesity.

Body weight was a secondary endpoint, measured at 13 weeks in people who averaged 93.7 kg at baseline. Ascletis reported placebo adjusted weight loss of 4.4%, 3.8% and 4.0% across the three dose groups, with p values between 0.001 and 0.003. The company said weight had not reached a plateau when the study ended, which, if confirmed in full data, would mean the trial stopped before the full effect on weight was seen. Ascletis also said ASC30 met all secondary endpoints and improved several cardiovascular risk factors. The release did not name those risk factors or give any figures for them, so that claim cannot be checked yet. The study is listed on the U.S. trial registry under the number NCT07321678.

What the press release leaves out

All headline figures use what Ascletis calls the efficacy estimand. The company defines it as the treatment effect in randomized eligible participants while they keep taking the drug, which sets aside what happens after people stop. An analysis that counts everyone assigned to treatment, including those who quit, would be expected to show a smaller effect, and the release does not include one. It also leaves out the raw HbA1c change in each arm, the size of the placebo group, and the share of people who reached common targets such as an HbA1c below 7%. Without those figures, the 1.7 point result from a 13 week trial cannot be compared cleanly with results from longer studies of other GLP 1 drugs.

Without those figures, the 1.7 point result from a 13 week trial cannot be compared cleanly with results from longer studies of other GLP 1 drugs.

Size and length also limit what the ASC30 diabetes trial can show. Only 77 people on the drug fed into the efficacy analysis, split across three dose groups, and treatment lasted 13 weeks. HbA1c reflects average blood sugar over roughly three months, so a 12 week reading captures an early response rather than a settled one. The three dose groups produced almost the same HbA1c result, so the study did not show added benefit from higher doses on its main measure. The release does not say when or where the full data will be published or presented, and no independent researchers have reviewed them. Statements by chief executive Jinzi Jason Wu that ASC30 could be best in class are company views.

Tolerability and liver tests in the release

Ascletis said ASC30 was well tolerated even though doses were raised quickly in small steps from a low starting amount. No participant left the study because of gastrointestinal side effects, according to the company. One person out of 80 treated with ASC30 stopped because of hiccups, a rate of 1.3%, and no one in the placebo group stopped for side effects. Ascletis said all drug related adverse events were mild or moderate, graded 1 or 2, and that there were no drug related serious adverse events. The release did not give rates of nausea, vomiting, diarrhea or constipation, the complaints most often linked to GLP 1 medicines. A low dropout rate in a short study does not show how many people felt unwell while staying on treatment.

The company also reported no rise in the liver markers ALT, AST or total bilirubin during treatment and said it saw no liver safety signal. Ascletis said the safety profile matched what it had seen in a separate Phase 2 study, NCT07002905, in people with obesity or overweight. Liver monitoring matters for any daily oral drug meant for long term use, and 13 weeks in 80 treated people is too short and too small to rule out rare problems. Ascletis said it expects gut tolerability to improve markedly in a planned Phase 3 diabetes program, where dose increases will be spaced further apart. That is a company expectation, not a trial result, and the release gave no start date or size for that program.

Where an oral small molecule GLP 1 fits

ASC30 is an oral small molecule GLP 1 receptor agonist, a chemical drug built to switch on the same receptor that peptide medicines such as semaglutide target. Small molecules avoid the hurdle of getting a fragile peptide through the gut, which is why several companies are testing them as daily pills. Ascletis describes ASC30 as a fully biased agonist, meaning it is designed to favor certain signaling routes inside the cell, but the release offers no clinical evidence that this design changes outcomes. Lilly's orforglipron uses the same broad approach, and readers can revisit its first obesity readout for comparison. AstraZeneca is testing its own oral GLP 1 drug, and its elecoglipron kidney data came out this week.

For now, obesity remains the lead program. Ascletis said two pivotal Phase 3 trials, AURORA-1 and AURORA-2, are enrolling about 4,600 adults with obesity or overweight in the U.S., Europe and Canada. The company expects topline results in the third quarter of 2028, a U.S. New Drug Application by the end of 2028 and a European marketing application in early 2029. Those dates are company forecasts that depend on enrollment, results and regulators. Ascletis said ASC30 could become the second oral small molecule GLP 1 drug available in the U.S. and Europe if approved. Until then it remains an unapproved compound, and no legitimate version exists outside clinical trials, so products sold online under its name carry real counterfeit risk.

Conclusion

The ASC30 diabetes trial gave Ascletis Pharma a positive topline result: placebo adjusted HbA1c drops of 1.6 to 1.7 points at 12 weeks, early weight loss and no gastrointestinal dropouts, the company said. The data cover 13 weeks, about 100 people and one analysis method, with no peer review yet. Readers should watch for side effect rates, an analysis that counts everyone treated, and details of the planned Phase 3 diabetes program. This report is research news, not medical advice.